Optimer Pharma Prices IPO

Optimer Pharmaceuticals Inc., a San Diego-based developer of anti-infective products, priced seven million common shares at $7 per share, for an IPO take of approximately $49 million. It originally planned to sell 5.25 million shares at between $12-$14 per share, and later lowered the range for $8-$9 per share. It will trade on the Nasdaq under ticker symbol OPTR, while Piper Jaffray and Jefferies & Co. served as co-lead underwriters. It has raised $67.7 million in VC funding from firms like ProQuest Investments, Formose Healthcare Investments and BB Biotech. www.optimerpharma.com< ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />